22157.jpg
Worldwide Nanobiotechnology Industry to 2029 - Featuring Aduro BioTech, Calando Pharmaceuticals and Baxter International Among Others
29. April 2021 07:28 ET | Research and Markets
Dublin, April 29, 2021 (GLOBE NEWSWIRE) -- The "Nanobiotechnology Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts,...
Unknown.png
Arch Therapeutics to Provide Corporate Update at the 2019 BIO CEO & Investor Conference
05. Februar 2019 07:50 ET | Arch Therapeutics, Inc.
FRAMINGHAM, Mass., Feb. 05, 2019 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices, will...
Unknown.png
Arch Therapeutics to Provide Corporate Update at the 11th Annual Biotech Showcase™ 2019 Conference on January 8th, 2019
20. Dezember 2018 07:50 ET | Arch Therapeutics, Inc.
FRAMINGHAM, Mass., Dec. 20, 2018 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices, will...
Unknown.png
Arch Therapeutics Receives 510(k) Clearance from the US FDA for AC5™ Topical Gel
17. Dezember 2018 07:50 ET | Arch Therapeutics, Inc.
FRAMINGHAM, Mass., Dec. 17, 2018 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices,...
Unknown.png
Arch Therapeutics Provided Corporate Update at the 11th Annual LD Micro Main Event
06. Dezember 2018 07:50 ET | Arch Therapeutics, Inc.
FRAMINGHAM, Mass., Dec. 06, 2018 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices,...
Unknown.png
Arch Therapeutics Announces Positive Outcome of Ruling from Japanese Intellectual Property High Court
04. Dezember 2018 07:50 ET | Arch Therapeutics, Inc.
FRAMINGHAM, Mass., Dec. 04, 2018 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices, is...